In CNS tumors, the most common targetable lesions were BRAF fusions (with KIAA1540 and other partners) that retained the active BRAF kinase domain, amenable to MAPK targeting with MEK inhibitors [50]. Here, MAP2K7 is linked to central nervous system neoplasm.